Merit Medical Systems Inc Dossier
Qualitative Analysis
Business overview
Merit Medical Systems, Inc. (NASDAQ: MMSI) is a leading global manufacturer and marketer of proprietary, disposable medical devices used in interventional, diagnostic, and therapeutic procedures. Founded in 1987 and headquartered in South Jordan, Utah, the company operates primarily across two newly reorganized product categories: Foundational (comprising access and enabling devices, representing approximately two-thirds of sales) and Therapeutic (comprising oncology, embolotherapy, and specialized intervention devices). Merit serves hospitals and clinics worldwide, with direct sales forces and distributor networks spanning the United States, Europe, the Middle East, Africa (EMEA), and Asia-Pacific.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-year operational and financial program introduced to drive sustainable growth, enhance profitability, and enforce capital discipline through the end of fiscal year 2026.
Expected impact: Targets an organic constant currency revenue CAGR of 5% to 7%, non-GAAP operating margins of 20.0% to 22.0% by 2026, and cumulative free cash flow of at least $400 million.
Strategic expansion into high-margin, wire-free, non-radioactive tumor localization and interventional oncology procedures, building upon the established SCOUT radar localization platform.
Expected impact: Establishes a comprehensive localization portfolio by combining radar (SCOUT) and ultrasound-enhanced (OneMark) technologies, targeting an estimated 1.3 million procedures annually in the US.
Enhancing the gastroenterology and endoscopy product lines through the integration of advanced ablation technologies, such as the C2 CryoBalloon system acquired from Pentax of America.
Expected impact: Projected to add $6 million to $8 million of revenue in 2026, leveraging Merit's existing commercial footprint in the gastroenterology market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire the FDA-cleared OneMark Detection Imaging System and OneMark Tissue Markers, expanding Merit's therapeutic oncology portfolio and strengthening its market leadership in wire-free, non-radioactive breast and soft tissue tumor localization.
Financial impact: Expected to contribute $2 million to $4 million in revenue and dilute non-GAAP EPS by $0.05 in 2026. Projected to contribute $14 million to $16 million in revenue and become accretive to non-GAAP EPS in 2027.
To acquire the C2 CryoBalloon device and related technology for precise ablation of soft tissue, expanding Merit's Endoscopy division portfolio to treat Barrett's esophagus and other gastrointestinal disorders.
Financial impact: Contributed approximately $1 million in revenue in late 2025. Projected to contribute $6 million to $8 million in revenue in 2026, with non-GAAP EPS accretion expected to begin in 2027.
To acquire patented hemostatic devices under the brand names StatSeal and WoundSeal, addressing a $350 million global market opportunity and complementing Merit's percutaneous interventional device portfolio.
Financial impact: Contributed $10 million to $11 million in revenue for the remainder of 2025. Expected to generate approximately $18 million in annualized revenue starting in fiscal year 2026 with accretive non-GAAP margins.